Stryker Corp. SYK -0.24% agreed to
acquire Mako Surgical Corp. MAKO +0.34%and its robotic-surgery
platform for roughly $1.65 billion, a move aimed at distinguishing Stryker's
line of replacement knees and hips for its increasingly cost-conscious
hospital customers. Mako shareholders will
receive $30 a share, an 86% premium to the stock's Tuesday closing price. The
Fort Lauderdale, Fla., company is expected to issue an additional four
million shares in connection with the deal. Mako makes a robotic arm
designed to help surgeons more precisely implant replacement knees and hips
during a procedure called Makoplasty. The product
is complementary to Stryker's existing line of replacement hip and knee
joints and could appeal to hospitals looking to improve procedural
efficiency. "Our combined expertise offers the potential to simplify
joint reconstruction procedures, reduce variability and enhance the surgeon
and patient experience," said Stryker President and Chief Executive
Kevin A. Lobo in a written statement. Markets reacted coolly to the deal, however, with some investors
questioning the relatively high purchase price. Stryker shares were off 2.1%
at $69.36 on the New York Stock Exchange at midday Wednesday. "They're paying a lot—around 13 times this year's
sales. That's a pretty big price," said Raj Denhoy,
a medical-devices analyst at Jefferies & Co. "Stryker has shown its
willingness to pay to expand into new areas." The price also reflected the lengths that medical-device
companies will go to jumpstart sales growth in the face of product
commoditization and broad economic pressures that have led health-care
providers and insurers to clamp down on costs. Stryker said that the addition
of Mako would help it cater to hospital and
insurance executives who increasingly want new devices to help reduce overall
costs, a growing focus area for the devices industry. "Robot-assisted procedures have the potential to aid
hospitals, third-party payors and patients as they
may reduce costs by shortening hospital stays and recovery periods and may
reduce the amount of rehabilitation and medication," said Yin Becker, a
Stryker spokeswoman, in an email. "We believe orthopaedic
surgical robotics provides an opportunity to expand and grow significantly
from its position today and has the potential to become a game-changing
technology longer term." Mako shares were up 82%
at $29.50 on the Nasdaq Stock Market at midday
Wednesday. As recently as March 2012, the stock traded for as high as $45. Mako's robots so far haven't experienced the uptake that
many investors had initially hoped, said Jefferies' Mr. Denhoy.
Knee implants in particular already have a high success rate, and some
surgeons have questioned the robot's value. However, adoption of the
company's hip-replacement product could improve because those procedures are
thought to be more difficult. In recent years, some patients have put off elective procedures
because of the sluggish economy, which has slowed growth in the market for
surgical knee and hip products. Meanwhile, hospitals looking to cut costs
have pressured prices by reducing their number of suppliers. In recent quarters, however, there have been signs of
stabilization in the joint-reconstruction market. Stryker has said it expects
revenue growth for the overall U.S. hip-and-knee market to rise in the low-
to midsingle-digit range. Stryker has sought to hedge against the sluggish orthopedics
market by expanding its offerings in surgical tools and neurovascular
products. The company, whose shares are up 26% year-to-date, is also
recovering from a series of problems related to some of its devices that have
resulted in product recalls. The acquisition is expected to reduce Stryker's adjusted
per-share earnings by about 10 cents to 12 cents in the first full year after
it closes, be neutral in the second year and add to the bottom line after
that. A Mako representative wasn't
immediately available to provide further comment. Write to Joseph Walker
at joseph.walker@wsj.com and
Tess Stynes attess.stynes@dowjones.com A version of this
article appeared September 26, 2013, on page B9 in the U.S. edition of The
Wall Street Journal, with the headline: Stryker Buys Robotic-Surgery Company. |